#United States #New York #The Gross Law Firm #class action lawsuit #Actinium Pharmaceuticals

Class Action Lawsuit Against Actinium Pharmaceuticals

On May 15, 2025, The Gross Law Firm announced the filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who acquired shares during the specified class period are encouraged to connect with the law firm for potential lead plaintiff appointment. Notably, appointment as lead plaintiff isn't mandatory to participate in any recovery from this legal action.

Important Dates and Allegations

The class period for this lawsuit covers purchases made between October 31, 2022, and August 2, 2024. The complaint highlights several allegations against Actinium Pharmaceuticals:

• - Misleading Communications: It claims that during the class period, the company issued materially false statements regarding its Phase 3 Sierra trial data. It suggests that the data might not align with FDA guidelines for approval concerning their targeted radiotherapy treatment, Iomab-B BLA.
• - Inadequate Disclosure: The firm alleges that the additional analyses meant to demonstrate improved overall survival trends were also unlikely to meet FDA requirements, thereby casting doubt on the potential approval of the Iomab-B application.
• - Negative Impact of Misstatements: As a result of the misleading statements made by the defendants, the lawsuit argues that shareholders were left with an inflated perception of the company's business prospects, leading to significant losses.

Steps for Shareholders

Shareholders who purchased shares of ATNM during the designated class period need to act promptly. The deadline to register for this class action is May 27, 2025. Those interested can register through The Gross Law Firm’s website.

Once registered, shareholders will be enrolled in a monitoring system to provide updates throughout the case proceedings. Importantly, there are no costs incurred for participating, and registration is crucial for those wishing to recover losses incurred due to the alleged misrepresentation of the company's financial standing.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized for its commitment to defending the rights of investors who have been affected by fraudulent practices or deceptive corporate behavior. Their aim is to ensure that companies are held accountable for their actions, contributing to more transparent market practices. With a focus on investments plagued by artificial inflation caused by misleading statements, the firm stands ready to advocate for affected shareholders.

For those with inquiries or who wish to pursue this matter further, they can get in touch via their New York office, or directly through email or phone.

Contact Information:

• - Address: The Gross Law Firm, 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

The Gross Law Firm emphasizes the importance of acting swiftly for potential plaintiffs, as the time-sensitive nature of this legal process demands immediate attention from shareholders affected during the stated class period.

In conclusion, shareholders of Actinium Pharmaceuticals should take note of this significant development and consider their legal options carefully to ensure they protect their investments from the consequences of the alleged corporate misconduct. This class action aims to facilitate recovery for those misled by the company's purportedly inaccurate statements regarding its operational effectiveness and regulatory compliance.